<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00723177</url>
  </required_header>
  <id_info>
    <org_study_id>#5725</org_study_id>
    <secondary_id>P50DA009236</secondary_id>
    <nct_id>NCT00723177</nct_id>
  </id_info>
  <brief_title>Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal</brief_title>
  <acronym>AV411</acronym>
  <official_title>The Safety, Tolerability and Preliminary Efficacy of AV411, a Glial Activation Inhibitor, in Heroin Abusers Under Conditions of Morphine Maintenance and Withdrawal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Repeated use and/or abuse of opioid medications is generally associated with a characteristic
      withdrawal syndrome that develops after cessation of drug administration. The present study
      is designed to evaluate the effectiveness of AV411 to alter opioid-induced withdrawal
      symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Opioid-induced cytokine release and glial activation has been proposed to directly contribute
      to the affective and physiological aspects of withdrawal. Furthermore, cytokine release
      following opioid administration has been hypothesized to be a limiting factor in both the
      duration and magnitude of opioid-induced analgesia. The two primary goals of our study are to
      assess AV411's ability to 1) reduce the opioid-withdrawal syndrome and 2) increase and
      prolong the analgesic effects of the mu-opioid agonist, oxycodone. To explore whether AV411
      decreases opioid-induced glial cell activation, some participants assigned to the placebo and
      high dose AV411 groups (n = 6 for each dose condition) will be studied twice with
      [11C]PK11195, a positron emission tomography (PET) radiotracer used to measure the peripheral
      benzodiazepine receptor (PBR) in the human brain. The PBR is a receptor located on the
      mitochondria of the microglia and can be used to examine microglial activation in various
      brain regions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Opioid Withdrawal Scale Score (SOWS)</measure>
    <time_frame>Measured at the end of each two-week maintenance period (i.e., Placebo, Low AV411, High AV411).</time_frame>
    <description>Measures severity of opioid withdrawal in opioid dependent populations (0-64). Larger values indicate more severe withdrawal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Effects of AV411 on the Analgesic Effects of Oxycodone.</measure>
    <time_frame>Measured at the end of each AV411 of the three two-week maintenance periods</time_frame>
    <description>The McGill Pain Questionnaire (Melzack, 1987) was used to assess pain experience immediately following the immersion of the hand in 4 degree Celsius water. Scores were added across all 15 items to generate a sum score, which ranged between 15 and 60. Larger scores indicate greater pain levels.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will receive placebo drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose AV411</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive a low dose of AV411</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose AV411</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive a high dose of AV411</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AV411</intervention_name>
    <description>Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks</description>
    <arm_group_label>Low-dose AV411</arm_group_label>
    <arm_group_label>High-dose AV411</arm_group_label>
    <other_name>ibudilast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (PCB)</intervention_name>
    <description>Placebo drug will be administered orally twice a day (BID) for two consecutive weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PCB or 0 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults between the ages of 21 and 45

          -  Current dependence on heroin according to (Diagnostic and Statistical Manual) DSM-IV
             criteria

          -  Non-treatment seeking

        Exclusion Criteria:

          -  Female participants who are currently pregnant or breastfeeding. Lack of effective
             birth control 10 days before Study Day 1 (15 days prior to the first PET scan)

          -  Self-reported use of methadone, buprenorphine, or levo-alpha-acetylmethadol (LAAM) in
             the past 14 days

          -  Participants who have a positive history of neurological illness (including epilepsy)
             or those who have received anti-convulsant therapy during the past 5 years

          -  Liver disease requiring medication or medical treatment, and/or aspartate or alanine
             aminotransferase levels greater than 3 times the upper limit of normal

          -  Gastrointestinal or renal disease that would significantly impair absorption,
             metabolism or excretion of study drug, or require medication or medical treatment

          -  Neurological or psychiatric disorders including psychosis, bipolar disorder, organic
             brain disease, any seizure history or other disorders that require treatment or that
             could make study compliance difficult

          -  Positive tuberculosis (PPD) TB skin test along with a clinical history and chest X-ray
             indicative of active tuberculosis. (Individuals who have a positive PPD test and have
             a negative chest X-ray, are not symptomatic for tuberculosis, and do not require
             anti-tuberculosis therapy will be eligible to participate. Participants will be asked
             if they ever tested positive for tuberculosis. If so, they will not be given a PPD and
             a chest X-ray and clinical history will be used for evaluation purposes).

          -  Presence or positive history of severe medical illness or any cardiovascular disease
             or heart abnormality, such as low hemoglobin (Hb &lt; 13 g/dL in males, Hb &lt; 11 g/dL in
             females), or BP &gt; 150/90.

          -  Requirement for any of the following medications (current or within the past 4 weeks):
             psychotropics (including sedative/hypnotics, antidepressants, neuroleptics),
             anticonvulsants, antihypertensives, antiarrhythmics, or antiretroviral medications,.
             Participants on any current psychoactive prescription medications will be excluded.

          -  Current dependence (by DSM-IV criteria) on methadone, LAAM, or buprenorphine

          -  Participants for whom detoxification is not &quot;clinically recommended&quot; such as those
             with a significant history of overdose following detoxification

          -  Participation in an investigational drug study within the past 3 months

          -  Hypersensitivity to any of the medications used in this study

          -  Participants who are positive for HIV or chronic active hepatitis

          -  Metal implants or paramagnetic objects contained within the body which may interfere
             with the MRI scan, as determined in consultation with a neuroradiologist and according
             to the guidelines set forth in the following reference book commonly used by
             neuroradiologists: &quot;Guide to MR procedures and metallic objects&quot; Shellock Frank G.,
             Lippincott Williams &amp; Wilkins Healthcare, Philadelphia, 2001.

          -  Lifetime exposure to radiation in the workplace, or participation in nuclear medicine
             procedures, including research protocols, in the past year

          -  Positive Allen Test indicating lack of collateral blood flow to hand

          -  History of Reynaud's syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra D Comer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute and Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute/Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cooper ZD, Johnson KW, Pavlicova M, Glass A, Vosburg SK, Sullivan MA, Manubay JM, Martinez DM, Jones JD, Saccone PA, Comer SD. The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol. 2016 Jul;21(4):895-903. doi: 10.1111/adb.12261. Epub 2015 May 14.</citation>
    <PMID>25975386</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <results_first_submitted>March 23, 2015</results_first_submitted>
  <results_first_submitted_qc>October 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2016</results_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioid withdrawal, analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data have been published in a peer-reviewed journal.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>This group received placebo AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally twice a day for two consecutive weeks</description>
        </group>
        <group group_id="P2">
          <title>Low-dose AV411</title>
          <description>This group will receive a low dose of AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally twice a day for two consecutive weeks</description>
        </group>
        <group group_id="P3">
          <title>High-dose AV411</title>
          <description>This group will receive a high dose of AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally twice a day for two consecutive weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>This group will receive placebo AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks</description>
        </group>
        <group group_id="B2">
          <title>Low-dose AV411</title>
          <description>This group will receive a low dose of AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks</description>
        </group>
        <group group_id="B3">
          <title>High-dose AV411</title>
          <description>This group will receive a high dose of AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="4.5"/>
                    <measurement group_id="B2" value="38" spread="5.3"/>
                    <measurement group_id="B3" value="38" spread="4.3"/>
                    <measurement group_id="B4" value="38" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Opioid Withdrawal Scale Score (SOWS)</title>
        <description>Measures severity of opioid withdrawal in opioid dependent populations (0-64). Larger values indicate more severe withdrawal.</description>
        <time_frame>Measured at the end of each two-week maintenance period (i.e., Placebo, Low AV411, High AV411).</time_frame>
        <population>Only 30 of the total number of 44 enrolled completed the study .</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This group will receive placebo AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks</description>
          </group>
          <group group_id="O2">
            <title>Low-dose AV411</title>
            <description>This group will receive a low dose of AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks</description>
          </group>
          <group group_id="O3">
            <title>High-dose AV411</title>
            <description>This group will receive a high dose of AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Opioid Withdrawal Scale Score (SOWS)</title>
          <description>Measures severity of opioid withdrawal in opioid dependent populations (0-64). Larger values indicate more severe withdrawal.</description>
          <population>Only 30 of the total number of 44 enrolled completed the study .</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="4"/>
                    <measurement group_id="O2" value="4" spread="2"/>
                    <measurement group_id="O3" value="24" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effects of AV411 on the Analgesic Effects of Oxycodone.</title>
        <description>The McGill Pain Questionnaire (Melzack, 1987) was used to assess pain experience immediately following the immersion of the hand in 4 degree Celsius water. Scores were added across all 15 items to generate a sum score, which ranged between 15 and 60. Larger scores indicate greater pain levels.</description>
        <time_frame>Measured at the end of each AV411 of the three two-week maintenance periods</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This group will receive placebo AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks</description>
          </group>
          <group group_id="O2">
            <title>Low-dose AV411</title>
            <description>This group will receive a low dose of AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks</description>
          </group>
          <group group_id="O3">
            <title>High-dose AV411</title>
            <description>This group will receive a high dose of AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Effects of AV411 on the Analgesic Effects of Oxycodone.</title>
          <description>The McGill Pain Questionnaire (Melzack, 1987) was used to assess pain experience immediately following the immersion of the hand in 4 degree Celsius water. Scores were added across all 15 items to generate a sum score, which ranged between 15 and 60. Larger scores indicate greater pain levels.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" spread="5"/>
                    <measurement group_id="O2" value="42" spread="7"/>
                    <measurement group_id="O3" value="38" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>We assessed for adverse events daily throughout the study and at 1 and 3 month follow-up time points. If a serious adverse events was experienced, it would have been reported to the appropriate oversight authorities within 24-48 hours.</time_frame>
      <desc>An adverse event (AE) is any symptom, sign, illness or experience that develops or worsens in severity during the course of the study. A serious adverse event is any AE that is: Fatal, Life-threatening, Requires or prolongs inpatient stay, Results in persistent or significant disability or incapacity.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>This group will receive placebo AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks</description>
        </group>
        <group group_id="E2">
          <title>Low-dose AV411</title>
          <description>This group will receive a low dose of AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks</description>
        </group>
        <group group_id="E3">
          <title>High-dose AV411</title>
          <description>This group will receive a high dose of AV411
AV411: Placebo, low, and high dose of AV411 will be administered orally BID for two consecutive weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI upset and Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sandra Comer PhD</name_or_title>
      <organization>NYSPI/Columbia University</organization>
      <phone>646 774-6146</phone>
      <email>SDC10@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

